Fos regulates age-dependent neuroinflammation in VAPBALS

This study utilizes a CRISPR/Cas9-generated Drosophila model of ALS8 to demonstrate that age-dependent neuroinflammation driven by glial cells and regulated by the transcription factor Fos (Kayak) is a critical mechanism underlying disease progression, where enhancing Fos activity in glia suppresses inflammation and improves motor function.

The Gist

The Big Picture: A Broken Factory and a Fire Alarm

Imagine your brain is a bustling, high-tech factory. Inside this factory, there are millions of workers (neurons) building and maintaining the machinery that lets you move your body.

This study focuses on a specific type of factory breakdown called ALS (Amyotrophic Lateral Sclerosis). In this disease, the factory workers start dying, causing the machinery to stop working, which leads to paralysis.

The scientists wanted to know: Why does the factory break down? They suspected that the factory wasn't just failing because the workers were tired; they thought the factory was on fire. Specifically, they believed the "security guards" (immune cells) were panicking and setting off false alarms, creating a chaotic, inflammatory environment that killed the workers.

The Experiment: Building a Fly Model

To study this without hurting humans, the scientists built a miniature version of the disease using fruit flies (Drosophila).

1. The Defect: They found a specific broken part in the factory called VAPB. In humans, a tiny typo in the VAPB gene causes a severe form of ALS.
2. The Fix: Instead of just adding extra copies of the broken part (which happens in older experiments), these scientists used CRISPR (a genetic "scissor") to edit the fly's DNA. They changed one tiny letter in the fly's VAP gene to match the human error.
3. The Result: These "mutant" flies looked normal when they were babies. But as they got older, they started stumbling, couldn't climb up walls, and died much younger than normal flies. This perfectly mimicked the human disease.

The Discovery: The Factory is on Fire (Neuroinflammation)

The scientists looked inside the heads of these sick flies and found something surprising. The factory wasn't just breaking down; it was on fire.

• The Fire: They found that the flies' immune systems were constantly screaming "FIRE!" even though there was no real danger. This is called neuroinflammation.
• The Smoke: This inflammation wasn't just a small spark; it was a low-grade, chronic fire that got worse as the flies aged. It involved multiple "fire alarm systems" (immune pathways) all going off at once.
• The Culprit: The fire wasn't started by the workers (neurons); it was started by the security guards (glial cells). These guards were overreacting, creating a toxic environment that eventually killed the neurons.

The Hero: The "Kayak" Paddle

The scientists then asked: "Can we put out this fire?"

They ran a massive search for a "fire extinguisher" and found a genetic switch called Kayak (which is the fly version of a human protein called Fos).

• The Analogy: Think of Kayak as the Captain of the Security Guard team.
  • Normal Captain: In a healthy factory, the Captain tells the guards, "Everything is fine, stand down." This keeps the fire alarms quiet.
  • The Problem: In the sick flies, the Captain was weak or missing, so the guards kept screaming "FIRE!" and the inflammation got out of control.

The Solution: Giving the Captain a Superpower

The scientists decided to test what happens if they make the Captain stronger.

1. The Test: They forced the glial cells (security guards) to produce extra Kayak (the Captain).
2. The Result:
   • The Fire Went Out: The extra Kayak told the guards to calm down. The inflammation dropped significantly.
   • The Factory Saved: The sick flies, who were previously stumbling and dying young, suddenly became much better at climbing. They lived longer and moved better.
   • The Reverse Test: When they removed the Captain (knocked down Kayak), the fire got even worse, and the flies got sick faster.

Why This Matters

This study is a big deal for three reasons:

1. It's Not Just the Neurons: It proves that in ALS, the problem isn't just the dying brain cells; it's the inflammatory reaction of the support cells (glia) around them.
2. The "Kayak" Connection: It identifies Kayak (Fos) as a master switch that controls this inflammation. If we can figure out how to boost this switch in humans, we might be able to calm the immune system and slow down ALS.
3. A New Strategy: Instead of trying to fix the broken VAPB protein (which is hard), this suggests we can treat the disease by calming the immune system's overreaction.

The Bottom Line

Imagine ALS as a factory where the security guards are having a panic attack and burning the place down. This paper found that a specific leader (Kayak/Fos) can tell the guards to relax. By boosting this leader, the scientists were able to stop the panic, save the factory workers, and keep the factory running longer. This gives hope for new treatments that focus on calming the brain's immune system rather than just trying to fix the broken parts.

Technical Summary

1. Problem Statement

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron loss. A specific familial form, ALS8, is caused by a P56S mutation in the VAPB gene (Vesicle-associated membrane protein-associated protein B). VAPB is an endoplasmic reticulum (ER) protein crucial for membrane contact sites (MCS) and cellular homeostasis.

• Knowledge Gap: While previous models (often based on transgenic overexpression) have shown motor deficits, the molecular mechanisms linking VAPB dysfunction to age-dependent neuroinflammation and the specific role of glial cells in driving disease progression remain poorly understood.
• Objective: To establish a robust, genome-edited Drosophila model of ALS8 (VAPBP58S) and investigate the role of neuroinflammation, specifically identifying the transcriptional regulators (like Fos) that modulate glial-driven immune responses and disease progression.

2. Methodology

The study employed a multi-faceted approach combining genome editing, transcriptomics, behavioral assays, and genetic manipulation in Drosophila melanogaster:

• Model Generation: The authors generated a new VAPBP58S mutant line using CRISPR/Cas9 genome editing to introduce the P58S mutation (orthologous to human P56S) directly into the endogenous VAP locus. This avoided artifacts associated with transgenic overexpression models.
• Phenotypic Characterization:
  • Lifespan Analysis: Survival curves for males and females.
  • Motor Function: Age-dependent negative geotaxis (climbing) assays performed at days 5, 10, 15, 20, and 25.
• Transcriptomics (RNA-Seq):
  • 3' mRNA Sequencing: Performed on heads and guts of male and female flies at various ages (Days 5, 15, 20).
  • Analysis: Differential gene expression (DEG) analysis, Gene Ontology (GO) enrichment, and pathway analysis (Toll, IMD, JNK, Jak-STAT).
  • Validation: qRT-PCR was used to confirm key immune markers (e.g., CecA1, Drs).
• Genetic Screens & Modulation:
  • Glial Enhancer/Suppressor Screen: Using RepoGal4 (glial driver), the authors screened knockdown (KD), overexpression (OE), dominant-negative (DN), and constitutive active (CA) lines for genes in the Toll and JNK pathways.
  • Targeted Manipulation: Specific focus on kayak (kay), the Drosophila ortholog of mammalian Fos. Both wild-type kay and a SUMO-conjugation resistant dominant-active variant (kayK357R or kaySCR) were overexpressed or knocked down in glia.
• Mechanistic Investigation: ChIP-seq data analysis (modERN) to determine if Kay directly binds to immune gene promoters.

3. Key Contributions

• Novel Disease Model: Created a homozygous viable, CRISPR-edited VAPBP58S fly model that recapitulates the shortened lifespan and progressive motor deficits of human ALS8 without the confounding effects of transgene overexpression.
• Identification of Glial Neuroinflammation: Demonstrated that neuroinflammation in ALS8 is glia-originated and age-dependent, characterized by a low-grade, broad upregulation of immune pathways (Toll, IMD, JNK, Jak-STAT).
• Discovery of Fos (Kayak) as a Key Modulator: Identified kayak (Fos) as a critical negative regulator of neuroinflammation in glial cells.
• Mechanistic Insight: Proposed a model where VAPB dysfunction disrupts ER-membrane contact sites, leading to altered kinase signaling (potentially involving TAK1/TBK1 orthologs), which reduces the phosphorylation/activity of the Kay/Jun (AP-1) complex, thereby failing to repress immune genes.

4. Key Results

A. Phenotypic Validation of the CRISPR Model

• Lifespan: VAPBP58S flies exhibited a significantly reduced median lifespan (22 days for males, 21.5 days for females) compared to wild-type controls (44 and 50 days, respectively).
• Motor Deficits: Flies showed progressive, age-dependent motor decline. While no defects were seen at Day 5, significant climbing deficits emerged by Day 10 and worsened until complete immobility by Day 25. This phenotype was observed in both sexes.

B. Transcriptomic Evidence of Neuroinflammation

• Global Immune Upregulation: RNA-seq of VAPBP58S heads revealed a broad, low-grade increase in immune gene expression with age.
• Pathway Activation: Upregulated genes included antimicrobial peptides (AMPs) from the IMD, Toll, JNK, and Jak-STAT pathways (e.g., Drosocin, Attacin, Bomanin).
• Neuronal Decline: Concurrently, genes involved in synaptic transmission, ion transport, and synaptic plasticity were downregulated, indicating accelerated neuronal aging.
• Gut vs. Brain: Unlike the brain, the gut transcriptome showed no significant inflammatory changes, suggesting the pathology is CNS-specific and not driven by a gut-brain axis in this model.

C. kayak (Fos) as a Critical Regulator

• Genetic Screen: A glial screen identified kayak (kay) as a potent suppressor of motor defects.
  • Knockdown (KD): Glial KD of kay in VAPBP58S flies accelerated motor deterioration and increased inflammation.
  • Overexpression (OE): Glial OE of wild-type kay or the dominant-active kayK357R (kaySCR) rescued motor function and extended lifespan.
• Inflammation Modulation:
  • Glial OE of kay or kaySCR significantly reduced the expression of inflammatory markers (AMPs) in VAPBP58S flies.
  • Conversely, kay KD exacerbated inflammation.
  • kaySCR (SUMO-resistant) showed equal or slightly better efficacy than wild-type kay, suggesting SUMOylation normally dampens Fos activity in this context.

D. Mechanism of Action

• Indirect Regulation: ChIP-seq analysis revealed that while Kay binds to many promoters, it does not directly bind to the promoters of the upregulated immune genes in this context.
• Proposed Model: The authors propose that Kay (as part of the AP-1 heterodimer with Jun/Jra) acts as a transcriptional repressor of immune genes. In VAPBP58S flies, age-dependent disruption of VAPB function likely impairs upstream kinases (e.g., TAK1), leading to reduced phosphorylation/activation of the Kay/Jun complex. This loss of repression allows chronic, low-grade inflammation to persist, driving neuronal death.

5. Significance

• Therapeutic Target: The study identifies Fos (Kayak) as a central negative regulator of neuroinflammation in ALS. Enhancing Fos activity in glial cells could be a viable therapeutic strategy to dampen neuroinflammation and slow disease progression.
• Glial-Centric Pathology: It reinforces the paradigm that ALS is not solely a motor neuron disease but involves a non-cell-autonomous mechanism where glial inflammation drives neuronal degeneration.
• Evolutionary Conservation: Since Fos is highly conserved, these findings suggest that targeting the Fos/Jun (AP-1) pathway in human microglia could offer new avenues for treating ALS8 and potentially other neurodegenerative disorders involving chronic inflammation.
• Model Improvement: The CRISPR-edited VAPBP58S model provides a more physiologically relevant tool for studying ALS pathogenesis compared to previous overexpression models.

In conclusion, this paper establishes a direct link between ER dysfunction (VAPB mutation), glial dysregulation of the AP-1 transcription factor (Fos), and age-dependent neuroinflammation, offering a clear mechanistic pathway for future ALS research and drug development.